(NASDAQ: CRDL) Cardiol Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 51.4%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.49%.
Cardiol Therapeutics's earnings in 2026 is -$24,846,153.On average, 5 Wall Street analysts forecast CRDL's earnings for 2026 to be -$49,657,359, with the lowest CRDL earnings forecast at -$82,278,343, and the highest CRDL earnings forecast at -$24,793,697. On average, 5 Wall Street analysts forecast CRDL's earnings for 2027 to be -$13,678,075, with the lowest CRDL earnings forecast at -$20,569,586, and the highest CRDL earnings forecast at -$10,101,136.
In 2028, CRDL is forecast to generate $6,725,345 in earnings, with the lowest earnings forecast at -$22,406,156 and the highest earnings forecast at $37,850,836.